Antihypertensive medications and the prevalence of hyperkalemia in a large health system

Hypertension

Volumn 67, Issue 6, 2016, Pages 1181-1188

  Chang, Alex R ^a,e   Sang, Yingying ^b   Leddy, Julia ^a   Yahya, Taher ^a   Kirchner, H Lester ^a   Inker, Lesley A ^c   Matsushita, Kunihiro ^b   Ballew, Shoshana H ^b   Coresh, Josef ^b   Grams, Morgan E ^b,d  

^a GEISINGER HEALTH SYSTEM   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e School of Medicine ^*  (United States)

Author keywords

antihypertensive; hyperkalemia; medications; potassium; renin angiotensin aldosterone system

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; THIAZIDE DIURETIC AGENT; ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; DRUG EFFECT; FEMALE; HEALTH CARE; HUMAN; HYPERKALEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; POTASSIUM BLOOD LEVEL; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; AGE DISTRIBUTION; CHEMICALLY INDUCED; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; HEALTH CARE DELIVERY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PENNSYLVANIA; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SEVERITY OF ILLNESS INDEX; SEX RATIO; STATISTICAL MODEL;

AGE DISTRIBUTION; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DELIVERY OF HEALTH CARE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERKALEMIA; HYPERTENSION; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; PENNSYLVANIA; PREVALENCE; PROGNOSIS; RENIN-ANGIOTENSIN SYSTEM; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION;

EID: 84963699424     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.116.07363     Document Type: Article

References (22)

1. Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, Weir MR, Fink JC, The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 2009 169 1156 1162. doi: 10.1001/archinternmed.2009.132
2. Luo J, Brunelli SM, Jensen DE, Yang A, Association between Serum Potassium and Outcomes in Patients with Reduced Kidney Function. Clin J Am Soc Nephrol 2016 11 90 100. doi: 10.2215/CJN.01730215
3. Rimmer JM, Horn JF, Gennari FJ, Hyperkalemia as a complication of drug therapy. Arch Intern Med 1987 147 867 869
4. Acker CG, Johnson JP, Palevsky PM, Greenberg A, Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. Arch Intern Med 1998 158 917 924
5. Weir MR, Rolfe M, Potassium homeostasis and renin-Angiotensin-Aldosterone system inhibitors. Clin J Am Soc Nephrol 2010 5 531 548. doi: 10.2215/CJN.07821109
6. Jain N, Kotla S, Little BB, Weideman RA, Brilakis ES, Reilly RF, Banerjee S, Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am J Cardiol 2012 109 1510 1513. doi: 10.1016/j.amjcard.2012.01.367
7. Bakris GL, Siomos M, Richardson D, Janssen I, Bolton WK, Hebert L, Agarwal R, Catanzaro D, ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int 2000 58 2084 2092. doi: 10.1111/j.1523-1755.2000.00381.x
8. Shah KB, Rao K, Sawyer R, Gottlieb SS, The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J Am Coll Cardiol 2005 46 845 849. doi: 10.1016/j.jacc.2005.06.010
9. Raebel MA, McClure DL, Simon SR, Chan KA, Feldstein A, Andrade SE, Lafata JE, Roblin D, Davis RL, Gunter MJ, Platt R, Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Pharmacoepidemiol Drug Saf 2007 16 55 64. doi: 10.1002/pds.1217
10. Kidney disease: Improving global outcomes (KDIGO) CKD work group KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013 3 1 150
11. Alderman MH, Piller LB, Ford CE, Probstfield JL, Oparil S, Cushman WC, Einhorn PT, Franklin SS, Papademetriou V, Ong ST, Eckfeldt JH, Furberg CD, Calhoun DA, Davis BR, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 2012 59 926 933. doi: 10.1161/HYPERTENSIONAHA.111.180554
12. Desai AS, Swedberg K, McMurray JJ, Granger CB, Yusuf S, Young JB, Dunlap ME, Solomon SD, Hainer JW, Olofsson B, Michelson EL, Pfeffer MA, CHARM Program Investigators Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. J Am Coll Cardiol 2007 50 1959 1966. doi: 10.1016/j.jacc.2007.07.067
13. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW, Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006 354 131 140. doi: 10.1056/NEJMoa053107
14. Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J, Evaluation of the treatment gap between clinical guidelines and the utilization of renin-Angiotensin-Aldosterone system inhibitors. Am J Manag Care 2015 21 11 suppl s212 s220
15. Luo J, Brunelli SM, Jensen DE, Yang A, Association between Serum Potassium and Outcomes in Patients with Reduced Kidney Function. Clin J Am Soc Nephrol 2016 11 90 100. doi: 10.2215/CJN.01730215
16. Yeh HL, Huang LY, Su S, Yang MC, Wang TC, Underuse of ACE inhibitors and angiotensin II receptor blockers among patients with diabetic nephropathy in Taiwan. Health Policy 2011 100 196 202. doi: 10.1016/j.healthpol.2010.11.010
17. Winkelmayer WC, Fischer MA, Schneeweiss S, Wang PS, Levin R, Avorn J, Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes. Am J Kidney Dis 2005 46 1080 1087. doi: 10.1053/j.ajkd.2005.08.018
18. Masoudi FA, Rathore SS, Wang Y, Havranek EP, Curtis JP, Foody JM, Krumholz HM, National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation 2004 110 724 731. doi: 10.1161/01.CIR.0000138934.28340.ED
19. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI, Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997 349 747 752
20. McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, Tsuyuki RT, White M, Rouleau J, Latini R, Maggioni A, Young J, Pogue J, Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999 100 1056 1064
21. Weinberg JM, Appel LJ, Bakris G, Gassman JJ, Greene T, Kendrick CA, Wang X, Lash J, Lewis JA, Pogue V, Thornley-Brown D, Phillips RA, African American Study of Hypertension and Kidney Disease Collaborative Research Group Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med 2009 169 1587 1594. doi: 10.1001/archinternmed.2009.284
22. Flack JM, Sica DA, Bakris G, Brown AL, Ferdinand KC, Grimm RH Jr, Hall WD, Jones WE, Kountz DS, Lea JP, Nasser S, Nesbitt SD, Saunders E, Scisney-Matlock M, Jamerson KA, International Society on Hypertension in Blacks Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension 2010 56 780 800. doi: 10.1161/HYPERTENSIONAHA.110.152892